39PD - Ultra-deep sequencing of circulating free DNA to identify predictive, mutated HSP90 clients in GALAXY-1 (NCT01348126), a randomized phase 2b study o...
|Date||27 March 2014|
|Session||Poster Discussion 1|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
D. Fennell1, J. Shaw2, I. El-Hariry3, V.M. Vukovic3, V. Reichert4, L.M. Martins5
Inhibition of Hsp90, a key molecular chaperone required for activation of many oncoproteins critical to NSCLC growth and aggressiveness, can lead to cancer cell death. Ganetespib (G) is a 2nd generation Hsp90 inhibitor (Hsp90i) that has shown single agent clinical activity in patients with tumors harboring ALK, KRAS, HER2, and BRAF mutations. Circulating free DNA (cfDNA) is present at low levels in plasma of healthy individuals allowing detection of somatic mutations by deep sequencing. The aim of this work was to determine the mutational spectrum of patients enrolled into the GALAXY-1 trial using this liquid biopsy strategy.